tradingkey.logo

Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention

ReutersMar 11, 2025 5:43 PM

- Gilead Sciences Inc GILD.O:

  • GILEAD SCIENCES PRESENTS FIRST CLINICAL DATA FOR INVESTIGATIONAL ONCE-YEARLY LENACAPAVIR FOR HIV PREVENTION

  • GILEAD SCIENCES: DATA SHOWS PROMISING ONCE-YEARLY LENACAPAVIR FOR PREP PHARMACOKINETIC PROFILES OVER 52 WEEKS

  • GILEAD SCIENCES: SAFETY DATA SHOWED BOTH FORMULATIONS OF ONCE-YEARLY LENACAPAVIR FOR PREP WERE WELL TOLERATED, WITH NO NEW SAFETY SIGNALS

  • GILEAD SCIENCES: NEW PREP MODALITY PREFERENCE DATA SHOWS PREFERENCE FOR TWICE-YEARLY LENACAPAVIR VERSUS ONCE DAILY ORALS IN PURPOSE 1 SURVEY PARTICIPANTS

  • GILEAD SCIENCES: NEW STUDY POPULATION DATA FROM PURPOSE 1 SHOW COMPARABLE PHARMACOKINETIC & SAFETY PROFILES FOR ADOLESCENT & ADULT TRIAL PARTICIPANTS

Source text: [ID:]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI